CN114466859A - 一种用于血管新生、***新生相关疾病的多肽及其用途 - Google Patents

一种用于血管新生、***新生相关疾病的多肽及其用途 Download PDF

Info

Publication number
CN114466859A
CN114466859A CN202080068534.1A CN202080068534A CN114466859A CN 114466859 A CN114466859 A CN 114466859A CN 202080068534 A CN202080068534 A CN 202080068534A CN 114466859 A CN114466859 A CN 114466859A
Authority
CN
China
Prior art keywords
polypeptide
cancer
disease
diseases
corneal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080068534.1A
Other languages
English (en)
Inventor
田中纯美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN114466859A publication Critical patent/CN114466859A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Abstract

一种用于血管新生/***新生，血管内皮机能异常相关疾病，尤其是癌症、眼科疾病、动脉硬化、心脑肾血管疾患、阿尔茨海默病、老化性疾病、瘢痕形成等疾病的预防、抑制和/或者治疗或促进现有治疗药物的代谢和速效性的辅助制剂的多肽或者包含该多肽作为活性有效成分组成的片段，以及其在制备用于预防、抑制和/或者治疗血管新生疾病、***新生相关疾病的药物中的用途。尤其是在癌症相关的疾病、动脉硬化、阿尔茨海默病、瘢痕形成、老化相关的预防和治疗中的用途，特别是在眼科血管新生相关的疾病的预防和治疗中的用途。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080068534.1A 2019-10-11 2020-10-12 一种用于血管新生、***新生相关疾病的多肽及其用途 Pending CN114466859A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910961935.9A CN112641928A (zh) 2019-10-11 2019-10-11 一种用于血管新生、***新生相关疾病的多肽及其用途
CN2019109619359 2019-10-11
PCT/CN2020/120360 WO2021068962A1 (zh) 2019-10-11 2020-10-12 一种用于血管新生、***新生相关疾病的多肽及其用途

Publications (1)

Publication Number Publication Date
CN114466859A true CN114466859A (zh) 2022-05-10

Family

ID=75343748

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910961935.9A Withdrawn CN112641928A (zh) 2019-10-11 2019-10-11 一种用于血管新生、***新生相关疾病的多肽及其用途
CN202080068534.1A Pending CN114466859A (zh) 2019-10-11 2020-10-12 一种用于血管新生、***新生相关疾病的多肽及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910961935.9A Withdrawn CN112641928A (zh) 2019-10-11 2019-10-11 一种用于血管新生、***新生相关疾病的多肽及其用途

Country Status (2)

Country Link
CN (2) CN112641928A (zh)
WO (1) WO2021068962A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947817A (zh) * 2023-02-22 2023-04-11 广州庆毅生物医药科技有限公司 一种肿瘤相关多肽及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190717A1 (en) * 2007-09-11 2010-07-29 Dorian Bevec Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
WO2015133459A1 (ja) * 2014-03-03 2015-09-11 国立大学法人東京大学 角膜疾患若しくは角膜損傷の予防、抑制又は治療剤、細胞シート、細胞培養補助剤、並びに細胞培養方法
CN106714821A (zh) * 2014-06-26 2017-05-24 埃克西金炎症有限公司 Jnk信号转导途径的细胞穿透肽抑制剂用于治疗多种疾病的新用途
CN107353333A (zh) * 2017-06-29 2017-11-17 西安交通大学医学院第附属医院 一种骨保护性分子Semaphorine3A及其制药应用
CN107810192A (zh) * 2015-02-23 2018-03-16 海鸥治疗简易股份公司 非天然的脑信号蛋白3及其医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010097182A1 (en) * 2009-02-25 2010-09-02 Eth Zurich Method for in vivo imaging of lymph node lymphangiogenesis by immuno-positron emission tomography and markers therefore
KR101551299B1 (ko) * 2013-05-23 2015-09-10 아주대학교산학협력단 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질
SI3189074T1 (sl) * 2014-09-05 2021-08-31 Rsem, Limited Partnership Sestavki in postopki za zdravljenje in preprečevanje vnetja
CN109652533A (zh) * 2019-01-11 2019-04-19 中国人民解放军总医院 一种用于检测引发心血管症状的其他***疾病的致病基因的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190717A1 (en) * 2007-09-11 2010-07-29 Dorian Bevec Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
WO2015133459A1 (ja) * 2014-03-03 2015-09-11 国立大学法人東京大学 角膜疾患若しくは角膜損傷の予防、抑制又は治療剤、細胞シート、細胞培養補助剤、並びに細胞培養方法
CN106714821A (zh) * 2014-06-26 2017-05-24 埃克西金炎症有限公司 Jnk信号转导途径的细胞穿透肽抑制剂用于治疗多种疾病的新用途
CN107810192A (zh) * 2015-02-23 2018-03-16 海鸥治疗简易股份公司 非天然的脑信号蛋白3及其医药用途
CN107353333A (zh) * 2017-06-29 2017-11-17 西安交通大学医学院第附属医院 一种骨保护性分子Semaphorine3A及其制药应用

Also Published As

Publication number Publication date
WO2021068962A1 (zh) 2021-04-15
CN112641928A (zh) 2021-04-13

Similar Documents

Publication Publication Date Title
Nakao et al. Lymphatics and lymphangiogenesis in the eye
CN106860855B (zh) 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
CN109384830B (zh) 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
CN108348572B (zh) 含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
CN105636590B (zh) 眼病的治疗剂或预防剂
JP5284948B2 (ja) 眼内高血圧を治療するための新たなアプローチ
KR20190093626A (ko) 황반변성의 신규 치료 방법
JP6640311B2 (ja) 軟骨細胞の細胞外基質由来ペプチド
Dumbrăveanu et al. A review of neovascular glaucoma. Etiopathogenesis and treatment
JP2020518287A (ja) 組み換え修飾された繊維芽細胞成長因子及びその治療用途
Song et al. Application and mechanism of anti-VEGF drugs in age-related macular degeneration
CN114466859A (zh) 一种用于血管新生、***新生相关疾病的多肽及其用途
CN108159051B (zh) 3-甲基腺嘌呤在制备治疗视网膜下纤维化的药物中的应用
WO2019229116A1 (en) Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
KR20170115731A (ko) 황반변성 예방 또는 치료용 약학조성물
WO2018171411A1 (zh) 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN109593117B (zh) 一种用于抑制血管新生的多肽cka18n及其应用
CN114652826B (zh) 抗egfr抗体的用途
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
WO2018157807A1 (zh) 多肽、多肽片段及其衍生物与应用
JPWO2020009248A1 (ja) 眼組織の線維化抑制用組成物
Lan et al. Forkhead Domain Inhibitor-6 Suppresses Corneal Neovascularization and Subsequent Fibrosis After Alkali Burn in Rats
CN108779173A (zh) 通过拮抗胎盘生长因子抑制眼后部纤维化
RU2714193C1 (ru) Способ лечения воспалительных или дистрофических заболеваний глаз
CN110585196B (zh) 一种治疗及预防眼科疾病的药物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination